These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9396248)

  • 1. [Effects of a thromboxane-synthetase inhibitor in patients with chronic persistent coughing and no airwayhyperresponsiveness].
    Nishi K; Mizuguchi M; Tachibana H; Watanabe K; Ooka T; Fujimura M; Matsuda T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Sep; 35(9):927-33. PubMed ID: 9396248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chronic persistent coughing successfully treated with ozagrel].
    Nishi K; Mizuguchi M; Tachibana H; Ooka T; Fujimura M; Matsuda T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Mar; 34(3):350-4. PubMed ID: 8778479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Thromboxane A2 synthetase inhibitor in asthma therapy].
    Machida K; Takagi K; Horiba M
    Nihon Rinsho; 1996 Nov; 54(11):3034-9. PubMed ID: 8950950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors.
    Umemura K; Nakashima M; Saruta T
    Life Sci; 1997; 60(18):1583-8. PubMed ID: 9126880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participation of thromboxane A(2) in the cough response in guinea-pigs: antitussive effect of ozagrel.
    Shinagawa K; Kojima M; Ichikawa K; Hiratochi M; Aoyagi S; Akahane M
    Br J Pharmacol; 2000 Sep; 131(2):266-70. PubMed ID: 10991919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thromboxane A2 metabolism and clinical effects of selective thromboxane A2 synthetase inhibitor in patients with chronic glomerulonephritis].
    Niwa T; Nomura T; Ozawa Y; Maeda K; Shibata M
    Nihon Jinzo Gakkai Shi; 1987 Jun; 29(6):655-65. PubMed ID: 3682335
    [No Abstract]   [Full Text] [Related]  

  • 7. [Thromboxane A2 synthase inhibitor and receptor antagonist].
    Minoguchi K; Adachi M
    Nihon Rinsho; 2001 Oct; 59(10):1986-91. PubMed ID: 11676143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostanoids and cough response to capsaicin in asthma and chronic bronchitis.
    Fujimura M; Kamio Y; Kasahara K; Bando T; Hashimoto T; Matsuda T
    Eur Respir J; 1995 Sep; 8(9):1499-505. PubMed ID: 8575575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of thromboxane A2 synthetase inhibitor (OKY-046) on leukotriene C4-induced airway hyperresponsiveness in guinea pigs].
    Tsukagoshi H; Yodonawa S; Kurosawa M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Jun; 31(6):707-11. PubMed ID: 8345703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of antigen-induced airway hyperresponsiveness in rats: effects of ozagrel (a thromboxane A2 synthase inhibitor) and of CV-3988 (a platelet activating factor antagonist).
    Misawa M; Chiba Y
    Res Commun Chem Pathol Pharmacol; 1994 Jun; 84(3):341-9. PubMed ID: 7938906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of branch retinal arterial occlusion with sodium ozagrel, a thromboxane A2 synthetase inhibitor.
    Kato H; Emura S; Takeuchi N; Enoki M; Oogushi K; Takashima T; Ohmori K; Saito I
    J Int Med Res; 1997; 25(2):108-11. PubMed ID: 9100166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ozagrel (OKY-046), a thromboxane synthetase inhibitor, on theophylline pharmacokinetics in asthmatic patients.
    Kawakatsu K; Kino T; Yasuba H; Kawaguchi H; Tsubata R; Satake N; Oshima S
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):158-63. PubMed ID: 2338368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger.
    Imamura T; Kiguchi S; Kobayashi K; Ichikawa K; Yamazaki Y; Kojima M
    Arzneimittelforschung; 2003; 53(10):688-94. PubMed ID: 14650360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboxane A2 synthetase inhibitor (OKY-046) improves abnormal mucociliary transport in asthmatic patients.
    Kurashima K; Ogawa H; Ohka T; Fujimura M; Matsuda T
    Ann Allergy; 1992 Jan; 68(1):53-6. PubMed ID: 1736720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction].
    Sakamoto T; Harimoto K; Inoue S; Konishi A
    No To Shinkei; 1996 Sep; 48(9):805-9. PubMed ID: 8888028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of combination therapy with disodium cromoglycate (DSCG) and Ozagrel on non-atopic asthmatics].
    Yoshida N; Suguro H; Hashimoto N; Majima T; Yamaguchi M; Horie T
    Arerugi; 1994 Oct; 43(10):1262-9. PubMed ID: 7826222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma.
    Kurosawa M
    Clin Ther; 1995; 17(1):2-11; discussion 1. PubMed ID: 7758058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of a specific thromboxane A2 synthetase inhibitor on lymphocyte and neutrophil functions in adult intractable asthmatics].
    Kanehiro A; Takahashi K; Soda R; Takata M; Takeda K; Sugano H; Yamagata K; Katagi Y; Kimura I
    Arerugi; 1992 May; 41(5):584-94. PubMed ID: 1325764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical effects of sodium ozagrel and urokinase in patients with acute cerebral infarction in the territory of the internal carotid artery].
    Itoh H; Yamatani K; Oshida N; Shioi M; Takaba M; Kamiyama H; Itoh M
    No To Shinkei; 1998 Feb; 50(2):147-55. PubMed ID: 9513204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia.
    Seki H; Kuromaki K; Takeda S; Kinoshita K; Satoh K
    Hypertens Pregnancy; 1999; 18(2):157-64. PubMed ID: 10476617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.